A 57-year-old woman has metastatic non-squamous NSCLC. Molecular testing shows ALK rearrangement and no EGFR mutation. She has liver metastases and

Question

A 57-year-old woman has metastatic non-squamous NSCLC. Molecular testing shows ALK rearrangement and no EGFR mutation. She has liver metastases and ECOG performance status 1. What is the most appropriate management?

Accepted Answer

First-line ALK tyrosine kinase inhibitor therapy

Answer

Platinum-etoposide as small-cell treatment

Answer

Surgical lobectomy with curative intent

Answer

No systemic treatment because liver metastases preclude therapy

Answer

Long-term macrolide therapy

ALK-rearranged metastatic NSCLC — SCE Respiratory MCQ

A 57-year-old woman has metastatic non-squamous NSCLC. Molecular testing shows ALK rearrangement and no EGFR mutation. She has liver metastases and ECOG performance status 1. What is the most appropriate management?